Of the 26 patients with detected mutations in both the CTC and the primary tumor, 15 (58%) patients had at least one matching mutation (CTC + Tumor KRAS match), while in 11 (42%) patients, the KRAS mutations differed between the CTCs and the tumor (CTC + Tumor KRAS unmatch; Fig. 4). Here, KRAS is linked to neoplasm.